FDA Seeks Input on Remote and Autonomous Medical Robots
A surgeon operating from another hospital gets everyone’s attention. But when we covered the 35-mile telesurgery case, the detail that stood out was the surgeon and team beside the patient, ready to intervene. That raises a question worth bringing into the FDA’s latest robotics discussion. What should the bedside team be able to see, hear and do if remote control is interrupted?
The FDA’s Center for Devices and Radiological Health released a discussion paper in November on how to evaluate the benefits and risks of medical robots with remote operation or some degree of autonomy. It covers surgery and other medical uses. The agency is gathering early feedback from healthcare professionals, patients, manufacturers and the public. The paper is an invitation to comment and carries no new requirements.
Remote operation and autonomy raise different questions
In remote operation, a person controls the device from another location. In a surgical case, that can raise questions about connection reliability, who can pause the system and how the bedside team would take over.
Autonomy refers to a device carrying out some part of a task with a degree of independence. That raises a different set of questions. How does the team know when the system is performing a task on its own? How does the system signal that it needs someone to intervene? And how will the people in the room practice recognizing that moment?
What OR teams can bring to the discussion
Picture an interruption halfway through a case. What information does anesthesia need immediately? Can the circulating nurse and scrub team tell who currently has control? If the team has to change course, is the equipment they need in the room, and has the handoff been rehearsed?
Those questions come from the workflow we deal with every day. A comment from someone who sets up the robot, works at the bedside or coordinates an emergency response can give the FDA a concrete scenario to consider alongside engineering and performance data.
The FDA’s hybrid public workshop runs December 2–3, 2026. Written comments are due January 5, 2027 under docket FDA-2026-N-13135. If you could ask the FDA to evaluate one part of a robotic handoff, what would it be?
U.S. Food and Drug Administration. “Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation Capabilities: Discussion Paper and Request for Feedback.” FDA, Nov. 2026, https://www.fda.gov/medical-devices/robotic-medical-devices/evaluating-benefit-risk-robotic-medical-devices-autonomous-or-remote-teleoperation-capabilities.
U.S. Food and Drug Administration. “Public Workshop: Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation Capabilities.” FDA, 2–3 Dec. 2026, https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/public-workshop-evaluating-benefit-risk-robotic-medical-devices-autonomous-or-remote-teleoperation.




Comments